Analyzing Rocket Pharmaceuticals (RCKT) and Its Rivals

Rocket Pharmaceuticals (NASDAQ: RCKT) is one of 295 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Rocket Pharmaceuticals to similar businesses based on the strength of its valuation, dividends, risk, analyst recommendations, earnings, profitability and institutional ownership.

Risk & Volatility

Rocket Pharmaceuticals has a beta of 4.22, suggesting that its share price is 322% more volatile than the S&P 500. Comparatively, Rocket Pharmaceuticals’ peers have a beta of 1.65, suggesting that their average share price is 65% more volatile than the S&P 500.

Institutional and Insider Ownership

49.5% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 5.3% of Rocket Pharmaceuticals shares are held by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Rocket Pharmaceuticals and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Rocket Pharmaceuticals N/A -$42.85 million -2.92
Rocket Pharmaceuticals Competitors $271.74 million -$19.68 million 79.83

Rocket Pharmaceuticals’ peers have higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Rocket Pharmaceuticals and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rocket Pharmaceuticals 0 2 1 0 2.33
Rocket Pharmaceuticals Competitors 1256 3653 12194 260 2.66

Rocket Pharmaceuticals presently has a consensus price target of $10.67, indicating a potential downside of 40.24%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.40%. Given Rocket Pharmaceuticals’ peers stronger consensus rating and higher possible upside, analysts clearly believe Rocket Pharmaceuticals has less favorable growth aspects than its peers.


This table compares Rocket Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Rocket Pharmaceuticals N/A -61.38% -32.46%
Rocket Pharmaceuticals Competitors -5,323.77% -107.94% -36.77%


Rocket Pharmaceuticals peers beat Rocket Pharmaceuticals on 9 of the 13 factors compared.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc., formerly Inotek Pharmaceuticals Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic that the Company has designed to lower intraocular pressure (IOP) by restoring the eye’s natural pressure control mechanism. The Company developed this molecule to selectively stimulate a particular adenosine subreceptor in the eye with the effect of augmenting the intrinsic function of the eye’s trabecular meshwork (TM). Its product pipeline includes trabodenoson monotherapy delivered in an eye drop formulation, as well as a fixed-dose combination (FDC), of trabodenoson with latanoprost given once-daily (QD). The Company is evaluating the potential of trabodenoson to slow the loss of vision associated with glaucoma and degenerative retinal diseases.

Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply